课题基金 / 基金详情

IL 6 + NEUPOGEN AFTER IFOSFAMIDE, CARBOPLATIN + ETOPOSIDE FOR NSC LUNG CANCER

IL 6 + NEUPOGEN AFTER IFOSFAMIDE, CARBOPLATIN + ETOPOSIDE FOR NSC LUNG CANCER
异环磷酰胺、卡铂依托泊苷后使用 IL 6 Neupogen 治疗 NSC 肺癌
批准号：
3741510
负责人：
CAROLYN WASSERHEIT
金额：
$0.0万
依托单位：
NEW YORK UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3741510
关键词：
cis platinum compound colony stimulating factor combination cancer therapy combination chemotherapy drug interactions drug screening /evaluation etoposide human subject human therapy evaluation ifosfamide interleukin 6 neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy nonsmall cell lung cancer recombinant proteins

项目摘要

项目成果

CAROLYN WASSERHEIT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objectives of this study are to evaluate the safety and tolerability of the simultaneous administration of rhIL-6 and Neupogen (rhG-CSF) following Ifosfamide, Carboplatin and Etoposide (ICE) chemotherapy in patients with advanced non-small cell lung carcinoma; to assess the biological activity and hematopoietic recovery observed during the administration of IL-6 + G-CSF
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
海外基金